Company intelligence / Profile preview
Blueberry Therapeutics
Alderley Edge, Cheshire, United Kingdomblueberrytherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
BB2603, a novel topical terbinafine antifungal product using nanotechnology, met primary and secondary endpoints in a Phase 2b trial for onychomycosis. The trial showed an 83.3% response rate at Week 16 after three months of treatment—significantly higher than placebo—with sustained efficacy at Week 52. Safety profile was excellent with no systemic exposure or serious adverse events reported. Planning for Phase 3 trials is underway.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Nanomedicinesnanopolymer drug delivery technologytopical small molecules (notably terbinafine)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
CMS (China Medical System Holdings) – partnership to commercialize BB2603 in ChinaOther partners/investors include Northern Powerhouse Investment Fund, Medical Incubator Japan, China Medical Venture Investment, A&B (HK) Company
Beyond the preview
Go deeper on Blueberry Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blueberry Therapeutics.